<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02632851</url>
  </required_header>
  <id_info>
    <org_study_id>EIL/aBr/2015</org_study_id>
    <nct_id>NCT02632851</nct_id>
  </id_info>
  <brief_title>Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution</brief_title>
  <official_title>Non-interventional Multicentric Study on Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bitop AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bitop AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational, non-interventional multicentric study compares the inhalation therapy on
      patients suffering on respiratory tract infections and/or acute bronchitis between Ectoin
      inhalation solution and Pari NaCl (0.9%) inhalation solution
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The assessment focuses on the bronchitis Severity Score (BSS) for standardized use in
      clinical studies with the outcome criteria of cough, sputum production, rales/rhonchi, chest
      pain during coughing and dysnoea
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bronchitis Severity Score on physician´s evaluation (5 point IMOS scale)</measure>
    <time_frame>day 7</time_frame>
    <description>Assessment of bronchits severity score on a 5 point IMOS scale (complete recovery, major improvement, slight to moderate improvement, no change, deterioration) of symptoms:
Cough, sputum production, rales/rhonchi, chest pain during coughing, dyspnoea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bronchitis symptoms evaluated on patients´ diaries (5 point scale)</measure>
    <time_frame>day 14</time_frame>
    <description>Assessment of bronchits symptoms on a 5 point scale (absent, mild, moderate, severe, very severe) of symptoms:
Cough, sputum production, rales/rhonchi, chest pain during coughing, dyspnoea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients´ evaluation of tolerability (4 point scale)</measure>
    <time_frame>day7</time_frame>
    <description>assessment of tolerability on a 4 point scale (bad, satisfied, good, very good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physicians´ evaluation of tolerability (4 point scale)</measure>
    <time_frame>day 7</time_frame>
    <description>assessment of tolerability on a 4 point scale (bad, satisfied, good, very good)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patients´ evaluation of efficacy (five point IMOS scale)</measure>
    <time_frame>day 7</time_frame>
    <description>assessment of tolerability on a five point IMOS scale (complete recovery, major improvement, slight to moderate improvement, no change, deterioration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physicians´ evaluation of efficacy (five point IMOS scale)</measure>
    <time_frame>day 7</time_frame>
    <description>assessment of tolerability on a five point IMOS scale (complete recovery, major improvement, slight to moderate improvement, no change, deterioration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number and type of adverse events</measure>
    <time_frame>day 7</time_frame>
    <description>incidence of adverse events and correlation with the therapy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">135</enrollment>
  <condition>Bronchitis</condition>
  <condition>Cough</condition>
  <condition>Sputum, Cellular Atypia</condition>
  <condition>Dyspnoea</condition>
  <arm_group>
    <arm_group_label>Ectoin inhalation solution</arm_group_label>
    <description>treatment according to instructions for use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pari NaCl inhalation solution (0.9%)</arm_group_label>
    <description>treatment according to instructions for use</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        primary care or ENT units study the therapeutic process in this obvservational trial in
        total of 120 patients suffering on respiratory tract infection and/or acute bronchitis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  according to instruction for use

        Exclusion Criteria:

          -  according to instruction for use
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Mösges, Prof Dr</last_name>
    <role>Study Chair</role>
    <affiliation>University of Cologne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facharzt für HNO, Allergologie</name>
      <address>
        <city>Cologne</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Matthys H, Kamin W. Positioning of the Bronchitis Severity Score (BSS) for standardised use in clinical studies. Curr Med Res Opin. 2013 Oct;29(10):1383-90. doi: 10.1185/03007995.2013.832183. Epub 2013 Aug 23. Review.</citation>
    <PMID>23927521</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>June 20, 2016</last_update_submitted>
  <last_update_submitted_qc>June 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inhalation</keyword>
  <keyword>isotonic saline</keyword>
  <keyword>NaCl solution 0.9 %</keyword>
  <keyword>Ectoin</keyword>
  <keyword>bronchitis</keyword>
  <keyword>respiratory tract infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Respiratory Aspiration</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

